Sanofi: Form 20-F for the period ended Dec 31, 2020
Filed with the SEC on Mar 4, 2021 and accepted by EDGAR at Mar 4, 2021, 10:22 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 12 months2020-01-01 to 2020-12-31 | EUR 12.16bn | ifrs-full:CostOfSales |
| Gross profit | 12 months2020-01-01 to 2020-12-31 | EUR 25.21bn | ifrs-full:GrossProfit |
| Operating income | 12 months2020-01-01 to 2020-12-31 | EUR 14.14bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2020-01-01 to 2020-12-31 | EUR 1.81bn | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2020-01-01 to 2020-12-31 | EUR 12.31bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months2020-01-01 to 2020-12-31 | EUR 9.77 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2020-01-01 to 2020-12-31 | EUR 9.82 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2020-01-01 to 2020-12-31 | EUR 7.45bn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | At period end2020-12-31 | EUR 13.91bn | ifrs-full:CashAndCashEquivalents |
| Total assets | At period end2020-12-31 | EUR 114.53bn | ifrs-full:Assets |
| Shareholders' equity | At period end2020-12-31 | EUR 63.00bn | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2020-12-31 | 1,250,690,553 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001121404-21-000004. Last ingested by Listed: Nov 5, 2026, 12:26 ET. Listed shows no prices and gives no investment advice.